evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

48 questions · 49 findings · 16 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 4.1%GRADE not reported 1 · 2%Very low 9 · 18.4%Low 24 · 49%Moderate 12 · 24.5%High 1 · 2%

160/4.5 mcg BDF single inhaler therapy vs current best practice

Fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Non‐fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).

1 finding from 1 review

SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA

Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma

SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Withdrawals due to adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).

1 finding from 1 review